(6-Chloro-2-Methylpyrimidin-4-Ylamino)-N-(2-Chloro-6-Methylphenyl)Thiazole-5-Carboxamide

The thiazole carboxamide scaffold, specifically (6-chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide (empirical formula C₁₆H₁₃Cl₂N₅OS, molecular weight 393.9 g·mol⁻¹), functions as a versatile intermediate for the synthesis of Type II kinase inhibitors. The compound incorporates a 2-chloro-6-methylphenyl motif that occupies the hydrophobic back pocket of the ATP-binding site, while the 6-chloro-2-methylpyrimidin-4-ylamino moiety engages the hinge region via a bidentate hydrogen-bonding network. Storage at -20 °C under inert atmosphere (argon or nitrogen, ≤5 ppm O₂) is mandated to prevent oxidative degradation of the thioether and amide functionalities. Solubility in dimethyl sulfoxide at 25 °C exceeds 50 mg·mL⁻¹; aqueous solubility at pH 7.4 phosphate-buffered saline remains below 0.1 µM, necessitating formulation with cyclodextrin or lipid-based carriers for in vivo studies. Residual solvent thresholds comply with ICH Q3C Option 2 limits, with the most restrictive specification for N,N-dimethylformamide at ≤880 ppm.

What Distinguishes This Thiazole Carboxamide from Analogous Hinge-Binding Scaffolds?

Comparative physicochemical profiling reveals that the concurrent presence of chlorine substituents on both the pyrimidine (6-Cl) and the phenyl ring (2-Cl) elevates lipophilicity while preserving aqueous kinetic solubility below the critical nucleation threshold, a balance not achieved by the unsubstituted pyrimidine analogue or the 2,6-dimethylphenyl variant. In vitro microsomal stability data from public screening panels (human liver microsomes, 1 mg·mL⁻¹ protein, 37 °C, 60 min incubation) indicate that the 6-chloro-2-methylpyrimidine moiety reduces NADPH-dependent oxidative debenzylation by CYP2C9 and CYP3A4 isoforms relative to the des-chloro pyrimidine comparator. Published data for this specific configuration remains limited; however, trends align with the established metabolic shielding effect of electron-withdrawing substituents on the pyrimidine 6-position. The table below summarizes key computed and experimental differentiation parameters.

Parameter	(6-Chloro-2-methylpyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide	2-(Pyrimidin-4-ylamino)-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide	2-[(6-Chloro-2-methylpyrimidin-4-yl)amino]-N-(2,6-dimethylphenyl)thiazole-5-carboxamide
Molecular Weight (g·mol⁻¹)	393.9	359.8	373.5
cLogP (Biobyte ClogP v4.3)	4.12	2.81	3.98
Topological Polar Surface Area (Ų)	91.2	91.2	91.2
Hydrogen Bond Donors	2	2	2
Hydrogen Bond Acceptors	6	6	6
Aqueous Solubility at pH 7.4 (µM, shake-flask, 24 h)	<0.1	<0.5	0.3

The 2-chloro-6-methylphenyl amide group additionally imparts a rotational barrier around the amide C–N bond measured by variable-temperature ¹H NMR as ΔG^‡ ≈ 68 kJ·mol⁻¹ in DMSO-d₆, which restricts conformational sampling and pre-organizes the scaffold for the DFG-out binding mode characteristic of imatinib and related inhibitors. By contrast, the 2,6-dimethylphenyl analogue exhibits a lower barrier (ΔG^‡ ≈ 62 kJ·mol⁻¹), correlating with a measurable reduction in target residence time on ABL1 kinase in published stopped-flow fluorescence studies.

Batch Release Specification and Control of Dehalogenated Impurities

Manufacturing at scale employs preparative HPLC purification on C18-bonded silica (column internal diameter 50 mm, acetonitrile/water gradient 0.1% trifluoroacetic acid) to isolate the neutral form. The following release criteria are applied under a quality system aligned with ICH Q7.

Test Parameter	Analytical Method	Acceptance Criterion
Appearance	Visual inspection (Ph. Eur. 2.2.1)	Off-white to pale yellow powder, free of visible extraneous matter
Identity (LC-MS)	ESI+ single quadrupole, 3.5 kV capillary	[M+H]+ at m/z 394.0 ± 0.5 Da; fragment at 249.1 Da
Purity (HPLC-UV)	USP <621>, C18, 254 nm	≥ 98.0% area, single impurity ≤ 0.5%
Water Content	Karl Fischer coulometry (USP <921>)	≤ 0.5% w/w
Residual Solvents	Headspace GC-FID (USP <467>)	Acetonitrile ≤ 410 ppm, DMF ≤ 880 ppm, Dichloromethane ≤ 600 ppm
Elemental Impurities	ICP-MS (ICH Q3D)	As ≤ 1.5 µg·g⁻¹, Cd ≤ 0.2 µg·g⁻¹, Hg ≤ 0.3 µg·g⁻¹, Pb ≤ 0.5 µg·g⁻¹

Particular attention is directed to the des-chloro byproduct, 2-[(2-methylpyrimidin-4-yl)amino]-N-(2-chloro-6-methylphenyl)thiazole-5-carboxamide, which arises from catalytic hydrogenolysis during final deprotection. Its relative retention time (RRT 0.82) is resolved with a resolution factor R_s ≥ 2.5. This impurity, when present above 0.15%, has been linked to a reproducible IC₅₀ shift of +8-fold in ABL1 autophosphorylation cellular assays (K562 cell line), mandating the 0.5% total impurity ceiling.

When Substituted Pyrimidinylamines Require Pre-activation for Amide Coupling

The 6-chloro-2-methylpyrimidine substituent introduces a steric and electronic encumbrance that suppresses direct acylation at the thiazole 2-amino nitrogen under standard carbodiimide conditions. Activation with 1,1′-carbonyldiimidazole (CDI, 1.5 eq) in anhydrous tetrahydrofuran at 0–5 °C, followed by addition of the amine component after 30 min, is the preferred protocol for constructing the amide bond with minimal racemization. When the carboxamide is subsequently employed as a building block for further elaboration, rigorous exclusion of strong bases is mandatory. Sodium hydride (≥1.2 eq) in N-methyl-2-pyrrolidone at 25 °C causes rapid dehalogenation at the pyrimidine 6-position, generating a reactive aryl anion intermediate that oligomerizes within 15 min as tracked by ReactIR at 1565 cm⁻¹. Lithium hexamethyldisilazide in tetrahydrofuran at -78 °C permits kinetic deprotonation of the amide NH without dechlorination for ≤2 h. For palladium-catalyzed cross-coupling (Buchwald-Hartwig, Suzuki-Miyaura), ligand choice is confined to XPhos or SPhos (2–5 mol%) with Pd₂(dba)₃ to avoid catalyst poisoning by the thioether sulfur. Pre-drying of the compound at 40 °C under vacuum (≤10 mbar) for 12 h is required when used in moisture-sensitive coupling reactions; water content above 0.1% extinguishes the catalytic cycle and lowers the turnover number by a factor of ≥10. Without a preceding header, the discussion moves directly into process safety considerations relevant to reaction scale-up. Differential scanning calorimetry (DSC) of the isolated solid, recorded at a scan rate of 4 °C·min⁻¹ in a sealed gold crucible, reveals an exothermic decomposition onset at 287 °C with an energy release of -920 J·g⁻¹. The adiabatic time-to-maximum-rate under a Φ-factor of 1.0 is less than 24 h at an onset temperature of 200 °C, classifying the material as potentially shock-sensitive and dictating that all hot operations remain below 80 °C. Process-scale handling of dry powder in hammer mills or micronization equipment requires inerting with nitrogen at ≤2% O₂ to suppress dust explosion hazard (minimum ignition energy measured as 10 mJ per ASTM E2019). When the compound is charged into jacketed glass-lined reactors (volume 500–2000 L), heel agitation with a retreat-curve impeller at 80–100 rpm must precede solvent addition to prevent caking on the vessel wall, a failure mode observed in three consecutive pilot batches where localized overheating led to 2.3% degradation impurity generation.

Inhibition Profiling and Selectivity Screening Cascades

The compound is primarily utilized as a late-stage intermediate for generating covalent and reversible Type II kinase inhibitor libraries. Direct screening of the intermediate against a panel of 468 human kinases (DiscoveRx KINOMEscan, 1 µM ATP-competitive format) reveals a Kd above 10 µM for all targets, confirming minimal off-target binding prior to warhead conjugation. This blank profile differentiates the material from the 2-(3-chlorophenyl)amino thiazole series, which exhibits micromolar affinity for CLK2 and DYRK1A and confounds target deconvolution. After derivatization to the corresponding acrylamide or vinyl sulfonamide, the resulting conjugates reproduce the binding kinetics expected of type II inhibitors: residence times exceed 120 min on non-phosphorylated ABL1, and selectivity scores (S(10) at 1 µM) fall below 0.02. The 2-chloro-6-methylphenyl substituent additionally imparts resistance to hydrolysis by human carboxylesterase CES1, with a half-life in human hepatocyte suspensions exceeding 6 h, whereas the 2,6-dimethyl analogue is cleaved with t_1/2 1.8 h. Stability data generated under ICH Q1A conditions guide storage and handling recommendations. The bulk solid, packaged in amber glass bottles under argon headspace, shows degradation of <0.2% at 25 °C/60% RH and <0.4% at 40 °C/75% RH over a 6-month interval, with no secondary degradation peaks exceeding the 0.1% reporting threshold. The primary degradant, the 5-carboxylic acid hydrolysis product, elutes at RRT 0.85 and is limited to ≤0.3% in the release specification. Photostability testing per ICH Q1B Option 1 demonstrates no significant change after exposure to 1.2 million lux·h of visible light and 200 W·h·m⁻² of UV-A when the container closure is opaque high-density polyethylene. Solutions in dimethyl sulfoxide at 10 mM stored in polypropylene vials at 4 °C undergo 3.2% degradation per month via slow oxidation of the thiazole sulfur; aliquoting and single-use thawing is enforced for any assay-ready plate preparation. When integrated into cassette-dosing pharmacokinetic studies (Sprague-Dawley rat, 1 mg·kg⁻¹ IV, 5 mg·kg⁻¹ PO), the downstream conjugated species derived from this intermediate exhibit moderate clearance (CL = 35 mL·min⁻¹·kg⁻¹) and oral bioavailability (F = 22%), though the intermediate itself is not dosed directly. Differences from the stand-alone methyl ester and free acid derivatives—which are prone to lactone formation and decarboxylation, respectively—render the carboxamide the preferred core scaffold for medicinal chemistry campaigns targeting DFG-out conformations.